Thymosin

Thymosin 5 mg is PrimeTime BioLabs' research-grade preparation of Thymosin Alpha-1, a naturally occurring thymic peptide first isolated from thymosin fraction 5. The product ships as a single-use, 5 mg lyophilized vial, sealed and light-protected to preserve peptide integrity in transit and storage, with a lot-specific label for batch traceability. Each vial corresponds to a Certificate of Analysis documenting the exact specifications of that shipped batch, so researchers can confirm identity and purity before use. This preparation is intended exclusively for qualified laboratory research and is not formulated, labeled, or supplied for human or veterinary use.

Thymosin Alpha-1 is a 28-residue, N-terminally acetylated peptide (sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH) derived from the precursor protein prothymosin-alpha. Published research has examined its involvement in T-cell maturation, cytokine signaling (including interleukin-2 and interferon-gamma pathways), and toll-like receptor–mediated innate immune signaling, positioning it as a recurring subject in immune-function and host-defense research models. This body of research spans in-vitro, preclinical, and — for the molecule itself in a pharmaceutical context — published human clinical studies conducted outside the United States, where a synthetic version has been evaluated for chronic hepatitis B under the trade name Zadaxin. That clinical literature describes Thymosin Alpha-1 as a pharmaceutical compound studied in patient populations; it does not establish safety, efficacy, or suitability for human use of PrimeTime's research-use-only preparation, which is manufactured and supplied strictly as a laboratory reference material. Researchers should treat published findings as scientific context for experimental design, not as guidance for use outside a laboratory setting.

Each lot of Thymosin 5 mg is third-party tested for purity, identity, and sterility. Analytical confirmation uses HPLC to establish chromatographic purity and mass spectrometry to verify molecular identity against the expected mass of the 28-residue sequence — the two methods serve as complementary, not interchangeable, checks. A batch-specific Certificate of Analysis is available for download, documenting the purity result, test methods, and analysis date tied to the lot number on the vial. Purity and identity testing describe the material as manufactured; they do not describe or imply therapeutic efficacy, clinical safety, or regulatory approval. A Certificate of Analysis is an analytical record, not a validation of any use beyond qualified laboratory research.

Thymosin 5 mg is distributed exclusively for qualified laboratory research. It carries no FDA approval as a PrimeTime product, is not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind, and must be handled only by trained laboratory personnel in a controlled research setting. Thymosin Alpha-1 as a molecule is not FDA-approved for any indication in the United States; it is approved internationally under the brand name Zadaxin in a number of countries for chronic hepatitis B. That international pharmaceutical approval applies to a different product manufactured under a separate regulatory framework and does not extend to, or validate, this research-use-only material.